Retatrutide
Triple agonist: GLP-1, GIP, and glucagon receptors for maximum metabolic impact.
- Typical dose
- 2 mg – 12 mg
- Frequency
- once weekly
- Route
- Subcutaneous
- Half-life
- 6 days
- Routes
- Subcutaneous
- Status
- Phase 3 trials: not yet FDA approved
Benefits
- Highest weight loss in trials (~24%)
- Blood sugar control
- Potential liver fat reduction
Dosing
A common research range for Retatrutide is 2 mg to 12 mg once weekly. Titrate gradually over 16+ weeks. These figures are reference points from published literature, not a prescription — your protocol should be set with a licensed provider.
Half-life
Retatrutide has an approximate half-life of 6 days. Vial can display informational half-life estimates when supported data is available. These estimates are not measured blood concentrations or dosing instructions.
Storage
2-8°C.
Reported side effects
- Nausea
- Diarrhea
- Vomiting
- Decreased appetite
Contraindications
- Personal/family history of MTC
- MEN 2 syndrome
Track Retatrutide with Vial
Vial logs every Retatrutide dose, organizes your schedule, and offers reconstitution math and supported half-life estimates. Tracking records stay on your device. A Vial Pro subscription is required. Download Vial on the App Store →
This page is for educational and harm-reduction purposes only. Retatrutide is not FDA-approved for most uses described here. Always consult a licensed physician before starting any peptide protocol. Vial does not sell peptides, recommend vendors, or provide medical advice.